[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 464
Citations 0
News From the Food and Drug Administration
April 21, 2015

First Biosimilar Product Approved

JAMA. 2015;313(15):1507. doi:10.1001/jama.2015.3309

The first biosimilar product in the United States recently gained approval from the Food and Drug Administration (FDA).

Sandoz’s Zarxio was approved for the same indications as Amgen’s Neupogen, which boosts the production of white blood cells in patients with cancer who are receiving myelosuppressive therapy or undergoing bone marrow transplantation.

A biosimilar product must be highly similar to a biologic product already on the market. Only minor differences in clinically inactive components are allowed.

First Page Preview View Large
First page PDF preview
First page PDF preview
×